Subscribe
shutterstock_1479442553_rafapress
rafapress / Shutterstock.com
20 September 2021AmericasMuireann Bolger

Supernus hits Zydus with repeat suit over migraine drug

Supernus Pharmaceuticals has once again accused Indian generic drugmaker Zydus Cadila and its US unit of allegedly infringing 10 patents with its copycat of Trokendi XR (topiramate), a drug for migraines and seizures.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Endo sues Indian drug maker over anti-smoking drug patent
10 August 2023   Patent-in-suit relates to a synthetic drug used to treat nicotine dependence | Development comes after USFood and Drug Administration sets new guidelines forcing the withdrawal of another big pharma firm’s rival drug.
Big Pharma
Zydus challenges ruling in Takeda antitrust dispute
16 June 2022   Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.
Americas
Fed Circuit opens door for additional pharma revenues in Supernus decision
24 January 2019   The US Court of Appeals for the Federal Circuit has overturned a reduction in the patent term adjustment owned by Supernus Pharmaceuticals.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Endo sues Indian drug maker over anti-smoking drug patent
10 August 2023   Patent-in-suit relates to a synthetic drug used to treat nicotine dependence | Development comes after USFood and Drug Administration sets new guidelines forcing the withdrawal of another big pharma firm’s rival drug.
Big Pharma
Zydus challenges ruling in Takeda antitrust dispute
16 June 2022   Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.
Americas
Fed Circuit opens door for additional pharma revenues in Supernus decision
24 January 2019   The US Court of Appeals for the Federal Circuit has overturned a reduction in the patent term adjustment owned by Supernus Pharmaceuticals.

More on this story

Big Pharma
Endo sues Indian drug maker over anti-smoking drug patent
10 August 2023   Patent-in-suit relates to a synthetic drug used to treat nicotine dependence | Development comes after USFood and Drug Administration sets new guidelines forcing the withdrawal of another big pharma firm’s rival drug.
Big Pharma
Zydus challenges ruling in Takeda antitrust dispute
16 June 2022   Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.
Americas
Fed Circuit opens door for additional pharma revenues in Supernus decision
24 January 2019   The US Court of Appeals for the Federal Circuit has overturned a reduction in the patent term adjustment owned by Supernus Pharmaceuticals.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims